Skip to Content

Rasagiline Disease Interactions

There are 5 disease interactions with rasagiline:

Major

Dopamine agonists (applies to rasagiline) hypotension

Major Potential Hazard, Moderate plausibility.

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.

References

  1. "Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.
  2. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol 30 (1990): 194-9
  4. "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim, Ridgefield, CT.
  5. Hoehn MM "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol 32 (1975): 50-1
  6. "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.
View all 6 references
Major

Dopaminergic antiparkinson agents (applies to rasagiline) psychosis

Major Potential Hazard, Moderate plausibility.

Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.

Major

Rasagiline (applies to rasagiline) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Rasagiline should not be used in patients with moderate to severe hepatic impairment. Patients with mild hepatic impairment should not exceed a dose of 0.5 mg daily.

Moderate

Rasagiline (applies to rasagiline) hypertension

Moderate Potential Hazard, Moderate plausibility.

Exacerbation of hypertension may occur during treatment with rasagiline. Dosage adjustment may be necessary if the elevation is sustained. Patients should be monitored for new onset hypertension or hypertension that is not well controlled after starting treatment.

Moderate

Rasagiline (applies to rasagiline) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Dose adjustment of rasagiline is not required for patients with mild or moderate renal impairment. However, rasagiline has not been studied in patients with severe renal impairment. Caution is advised if used.

Rasagiline drug interactions

There are 492 drug interactions with rasagiline

Rasagiline alcohol/food interactions

There are 4 alcohol/food interactions with rasagiline

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.